<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231565</url>
  </required_header>
  <id_info>
    <org_study_id>PL10</org_study_id>
    <nct_id>NCT04231565</nct_id>
  </id_info>
  <brief_title>Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.</brief_title>
  <acronym>ALTHBV</acronym>
  <official_title>Study on Therapeutic Effects and Safety of Nucleoside (Acid) Analogues Treatment in Patients With Chronic Hepatitis B With Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues
      treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus
      DNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis b virus infection has always been a global public health problem that endangers
      national health. Current clinical guidelines do not recommend antiviral therapy for people
      with positive hepatitis b-DNA and normal Alanine Aminotransferase, but studies have found
      that viral replication is associated with an increased risk of cirrhosis and liver tumors.
      Nucleoside (acid) analogues can effectively inhibit viral reverse transcriptase, reduce HBV
      viral load in the blood, thereby reducing secondary inflammation, and contribute to liver
      cell regeneration and disease recovery. And its side effect is small, adverse reaction rate
      is low, use safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hepatitis b s antigen loss rate</measure>
    <time_frame>144 week</time_frame>
    <description>Hepatitis b s antigen become negative and quantitative analysis below the upper limit of test value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatitis b e antigen loss rate</measure>
    <time_frame>0 week,12 week,24 week,36 week,48 week,72 week,96 week,120 week,144 week</time_frame>
    <description>Hepatitis b e antigen would be tested to know the ratio of patients with negative hepatitis B e antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis b virus(HBV) DNA undetectable rate</measure>
    <time_frame>0 week,12 week,24 week,36 week,48 week,72 week,96 week,120 week,144 week</time_frame>
    <description>Hepatitis b virus DNA would not be detected if it below the upper limit of test value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis b virus(HBV) RNA undetectable rate</measure>
    <time_frame>0 week,12 week,24 week,36 week,48 week,72 week,96 week,120 week,144 week</time_frame>
    <description>Hepatitis b virus RNA would not be detected if it below the upper limit of test value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis B Virus</condition>
  <arm_group>
    <arm_group_label>TAF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50 patients would not receive treatment from baseline to life-long.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide Fumarate</intervention_name>
    <description>Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.</description>
    <arm_group_label>TAF group</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive hepatitis b surface antigen and hepatitis b antibody &gt; 0.5 year;

          -  Age from 18 to 65 years old;

          -  Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;

          -  Positive Hepatitis b virus(HBV);

          -  Do not receive nucleotide/nucleoside analogues or interferon treatment in the past
             half year.

        Exclusion Criteria:

          -  Other active liver diseases;

          -  Hepatocellular carcinoma or other malignancy;

          -  Pregnancy or lactation;

          -  Human immunodeficiency virus infection or congenital immune deficiency diseases;
             5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using
             glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering
             inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Wang, Doctor</last_name>
    <phone>+8618814369232</phone>
    <email>wanglu910525@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>hepatitis B virus</keyword>
  <keyword>nucleoside</keyword>
  <keyword>nucleotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

